{
    "symbol": "STIM",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-11 13:00:24",
    "content": " Total revenue was $16.5 million, up 20% over the third quarter of 2021. This represents the third straight quarter of over 15% year-over-year growth and the second straight quarter during, which we delivered revenue of over $16 million, bringing us back to consistent levels of top line performance that the business has not seen since 2019. U.S. NeuroStar revenue was $3.9 million, up 51% over the third quarter of 2021. The U.S. treatment session revenue was an all-time record of $11.9 million, up 16% over the third quarter 2021. For example, our recently launched Tap into a New Possibility campaign aimed at driving awareness among patients and their caregivers, drove over 30 million impressions in Q3, a 150% increase, as compared to campaigns run in the prior year, resulting in 1,000s of new patients beginning their search for a NeuroStar treatment. Total revenue for the third quarter was $16.5 million, an increase of 20% over third quarter 2021 revenue of $13.8 million. U.S. NeuroStar Advanced Therapy system revenue was $3.9 million, representing a 51% increase as compared to the prior year revenue of $2.6 million. U.S. treatment session revenue was $11.9 million, an increase of 16% over third quarter 2021 revenue of $10.3 million."
}